Differential effects of paraoxonase 1 (PON1) polymorphisms on cancer risk: Evidence from 25 published studies

Molecular Biology Reports

Volumn 39, Issue 6, 2012, Pages 6801-6809

  Fang, Dai Hua ^a   Fan, Cong Hai ^a   Ji, Qiang ^a   Qi, Bo Xiang ^a   Li, Juan ^a   Wang, Lu ^a  

^a XUZHOU CHILDREN S HOSPITAL   (China)

Author keywords

Cancer; Meta analysis; Paraoxonase 1; Polymorphism

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1;

ALLELE; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; GENE ACTIVITY; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; ONCOGENE; OSTEOSARCOMA; OVARY CANCER; PON1 GENE; PROSTATE CANCER; RISK ASSESSMENT;

ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; NEOPLASMS; ODDS RATIO; POLYMORPHISM, GENETIC; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA;

EID: 84864285712     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-012-1505-3     Document Type: Article

References (43)

1. Cejas P, Casado E, Belda-Iniesta C, De Castro J, Espinosa E, Redondo A, Sereno M, Garcia-Cabezas MA, Vara JA, Domin-guez-Caceres A, Perona R, Gonzalez-Baron M (2004) Implications of oxidative stress and cell membrane lipid peroxidation in human cancer (Spain). Cancer Causes Control 15(7):707-719. doi:10.1023/B:CACO.0000036189.61607.52 (Pubitemid 39066212)
2. Ames BN (1983) Dietary carcinogens and anticarcinogens. Oxygen radicals and degenerative diseases. Science 221(4617): 1256-1264
3. Klaunig JE, Kamendulis LM (2004) The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 44:239-267. doi:10.1146/annurev. pharmtox.44.101802.121851 (Pubitemid 38263841)
4. Wiseman H, Halliwell B (1996) Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J 313(1):17-29 (Pubitemid 26013419)
5. Stevens VL, Rodriguez C, Talbot JT, Pavluck AL, Thun MJ, Calle EE (2008) Paraoxonase 1 (PON1) polymorphisms and prostate cancer in the CPS-II nutrition cohort. Prostate 68(12):1336-1340. doi:10.1002/pros.20796
6. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE (1993) The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 3(1):73-76. doi: 10.1038/ng0193-73 (Pubitemid 23063292)
7. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE (1996) The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 14(3):334-336. doi:10.1038/ng1196-334
8. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ (1998) Mice lacking serum paraoxonase are susceptible to organophos-phate toxicity and atherosclerosis. Nature 394(6690):284-287. doi:10.1038/28406 (Pubitemid 28335041)
9. Aynacioglu AS, Cascorbi I, Mrozikiewicz PM, Nacak M, Tapa-nyigit EE, Roots I (1999) Paraoxonase 1 mutations in a Turkish population. Toxicol Appl Pharmacol 157(3):174-177. doi: 10.1006/taap.1999.8690 (Pubitemid 29283460)
10. Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Terada KY, Goodman MT (2008) Genetic polymorphisms in the Paraoxonase 1 gene and risk of ovarian epithelial carcinoma. Cancer Epidemiol Biomarkers Prev 17(8):2070-2077. doi: 10.1158/1055-9965.EPI-08-0145
11. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN (1997) Effect of the molecular polymorphisms of human parao-xonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol 122(2):265-268. doi:10.1038/sj.bjp. 0701390 (Pubitemid 27397197)
12. Li WF, Costa LG, Richter RJ, Hagen T, Shih DM, Tward A, Lusis AJ, Furlong CE (2000) Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 10(9):767-779 (Pubitemid 32042829)
13. Leviev I, Negro F, James RW (1997) Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of parao-xonase associated with the (Leu-Met54) polymorphism. Arte-rioscler Thromb Vasc Biol 17(11):2935-2939 (Pubitemid 28016045)
14. Leviev I, Deakin S, James RW (2001) Decreased stability of the M54 isoform of paraoxonase as a contributory factor to variations in human serum paraoxonase concentrations. J Lipid Res 42(4):528-535 (Pubitemid 32366995)
15. Aksoy-Sagirli P, Cakmakoglu B, Isbir T, Kaytan-Saglam E, Kizir A, Topuz E, Berkkan H (2011) Paraoxonase-1 192/55 polymorphisms and the risk of lung cancer in a Turkish population. Anticancer Res 31(6):2225-2229
16. Gallicchio L, McSorley MA, Newschaffer CJ, Huang HY, Thuita LW, Hoffman SC, Helzlsouer KJ (2007) Body mass, polymorphisms in obesity-related genes, and the risk of developing breast cancer among women with benign breast disease. Cancer Detect Prev 31(2):95-101. doi:10.1016/j.cdp.2007.02.004 (Pubitemid 46669815)
17. Searles Nielsen S, Mueller BA, De Roos AJ, Viernes HM, Farin FM, Checkoway H (2005) Risk of brain tumors in children and susceptibility to organophosphorus insecticides: the potential role of paraoxonase (PON1). Environ Health Perspect 113(7):909-913 (Pubitemid 40984194)
18. Arpaci A, Gormus U, Dalan B, Berkman S, Isbir T (2009) Investigation of PON1 192 and PON1 55 polymorphisms in ovarian cancer patients in Turkish population. In Vivo 23(3): 421-424
19. Antognelli C, Mearini L, Talesa VN, Giannantoni A, Mearini E (2005) Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer. Prostate 63(3):240-251. doi:10.1002/pros.20184 (Pubitemid 40571058)
20. Martinez C, Molina JA, Alonso-Navarro H, Jimenez-Jimenez FJ, Agundez JA, Garcia-Martin E (2010) Two common nonsynony-mous paraoxonase 1 (PON1) gene polymorphisms and brain astrocytoma and meningioma. BMC Neurol 10:71. doi: 10.1186/1471-2377-10-71
21. Handoll HH (2006) Systematic reviews on rehabilitation interventions. Arch Phys Med Rehabil 87(6):875. doi:10.1016/j.apmr. 2006.04.006 (Pubitemid 43767714)
22. Midgette AS, Wong JB, Beshansky JR, Porath A, Fleming C, Pauker SG (1994) Cost-effectiveness of streptokinase for acute myocardial infarction: a combined meta-analysis and decision analysis of the effects of infarct location and of likelihood of infarction. Med Decis Making 14(2):108-117 (Pubitemid 24116539)
23. Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127(9):820-826 (Pubitemid 27465551)
24. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629-634 (Pubitemid 27387172)
25. Antognelli C, Del Buono C, Ludovini V, Gori S, Talesa VN, Crino L, Barberini F, Rulli A (2009) CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case-control study. BMC Cancer 9:115. doi: 10.1186/1471-2407-9-115
26. Uyar OA, Kara M, Erol D, Ardicoglu A, Yuce H (2011) Investigating paraoxonase-1 gene Q192R and L55M polymorphism in patients with renal cell cancer. Genet Mol Res 10(1):133-139. doi:10.4238/vol10-1gmr927
27. Rajaraman P, Hutchinson A, Rothman N, Black PM, Fine HA, Loeffler JS, Selker RG, Shapiro WR, Linet MS, Inskip PD (2008) Oxidative response gene polymorphisms and risk of adult brain tumors. Neuro Oncol 10(5):709-715. doi:10.1215/15228517-2008-037
28. Ozturk O, Kagnici OF, Ozturk T, Durak H, Tuzuner BM, Ki-sakesen HI, Cakalir C, Isbir T (2009) 192R allele of paraoxanase 1 (PON1) gene as a new marker for susceptibility to bladder cancer. Anticancer Res 29(10):4041-4046
29. Ergen A, Kilicoglu O, Ozger H, Agachan B, Isbir T (2011) Paraoxonase 1 192 and 55 polymorphisms in osteosarcoma. Mol Biol Rep 38(6):4181-4184. doi:10.1007/s11033-010-0538-8
30. Hussein YM, Gharib AF, Etewa RL, ElSawy WH (2011) Association of L55 M and Q192R polymorphisms in paraoxonase 1 (PON1) gene with breast cancer risk and their clinical significance. Mol Cell Biochem 351(1-2):117-123. doi:10.1007/s11010-011-0718-4
31. Lee CH, Lee KY, Choe KH, Hong YC, Kim YD, Kang JW, Kim H (2005) Effects of oxidative DNA damage induced by polycy-clic aromatic hydrocarbons and genetic polymorphism of the paraoxonase-1 (PON1) gene on lung cancer. J Prev Med Public Health 38(3):345-350
32. Kerridge I, Lincz L, Scorgie F, Hickey D, Granter N, Spencer A (2002) Association between xenobiotic gene polymorphisms and non-Hodgkin's lymphoma risk. Br J Haematol 118(2):477-481 (Pubitemid 34994652)
33. Lincz LF, Kerridge I, Scorgie FE, Bailey M, Enno A, Spencer A (2004) Xenobiotic gene polymorphisms and susceptibility to multiple myeloma. Haematologica 89(5):628-629 (Pubitemid 38691261)
34. Sun Y (1990) Free radicals, antioxidant enzymes, and carcino-genesis. Free Radic Biol Med 8(6):583-599 (Pubitemid 20204421)
35. Karaman E, Uzun H, Papila I, Balci H, Ozdilek A, Genc H, Yanardag H, Papila C (2010) Serum paraoxonase activity and oxidative DNA damage in patients with laryngeal squamous cell carcinoma. J Craniofac Surg 21(6):1745-1749. doi:10.1097/SCS. 0b013e3181f4040a
36. Elkiran ET, Mar N, Aygen B, Gursu F, Karaoglu A, Koca S (2007) Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population. BMC Cancer 7:48. doi: 10.1186/1471-2407-7-48 (Pubitemid 46510374)
37. Akcay MN, Polat MF, Yilmaz I, Akcay G (2003) Serum parao-xonase levels in pancreatic cancer. Hepatogastroenterology 50(2):ccxxv-ccxxvii
38. Akcay MN, Yilmaz I, Polat MF, Akcay G (2003) Serum parao-xonase levels in gastric cancer. Hepatogastroenterology 50(2): cclxxiii-cclxxv
39. Garin MC, James RW, Dussoix P, Blanche H, Passa P, Froguel P, Ruiz J (1997) Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 99(1):62-66. doi: 10.1172/JCI119134 (Pubitemid 27058295)
40. Naidu R, Har YC, Taib NA (2010) Genetic Polymorphisms of paraoxonase 1 (PON1) Gene: association Between L55 M or Q192R with breast cancer risk and clinico-pathological parameters. Pathol Oncol Res. doi:10.1007/s12253-010-9267-5
41. Minelli C, Thompson JR, Abrams KR, Thakkinstian A, Attia J (2005) The choice of a genetic model in the meta-analysis of molecular association studies. Int J Epidemiol 34(6):1319-1328. doi:10.1093/ije/dyi169 (Pubitemid 41819539)
42. Ambrosone CB (2000) Oxidants and antioxidants in breast cancer. Antioxid Redox Signal 2(4):903-917 (Pubitemid 32062336)
43. Delimaris I, Faviou E, Antonakos G, Stathopoulou E, Zachari A, Dionyssiou-Asteriou A (2007) Oxidized LDL, serum oxidiz-ability and serum lipid levels in patients with breast or ovarian cancer. Clin Biochem 40(15):1129-1134. doi:10.1016/j.clinbiochem.2007.06.007 (Pubitemid 47379323)